Clinnova — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$300,025	118
2024	Research	$38,981	6
2022	Research	$13,224	6
2021	Research	$437,177	4

Breakdown

Who paid Research payments · program years 2021–2025

Novartis Pharmaceuticals Corporation $437,177 4 payments
Boehringer Ingelheim International GmbH $322,922 122 payments
E.R. Squibb & Sons, L.L.C. $16,085 2 payments
Regeneron Pharmaceuticals, Inc. $13,224 6 payments

Studies the money was for Research payments · program years 2021–2025

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ensovibep (Mp0420) in Ambulatory Adult Patients With Symptomatic Covid-19 (The Empathy Trial) $437,177 4 payments
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis $245,959 93 payments
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis $54,067 25 payments
A Phase 1/2/3 Adaptive Study to Evaluate the Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Patients Without Risk Factors for Progression to Severe Disease $13,224 6 payments
BI 456906 in NASH F2/F3 - pivotal trial $12,362 2 payments
BI 456906 in NASH F4 - pivotal trial $10,535 2 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn s Disease $9,257 1 payment
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn s Disease $6,828 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.